ArticleRestorative dentistry & endodontics2025
Resolvin E1 incorporated carboxymethyl chitosan scaffold accelerates repair of dental pulp stem cells under inflammatory conditions: a laboratory investigation.
Article in Restorative dentistry & endodontics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: This study fabricated and characterized a resolvin E1 (RvE1)-loaded carboxymethyl chitosan (CMC) scaffold and determined its cytotoxicity and mineralization potential on inflamed human dental pulp stem cells (hDPSCs). Methods: CMC scaffold incorporated with two concentrations of RvE1 (100 and 200 nM) was fabricated and characterized. The scaffolds' porosity, drug release kinetics, and degradation were assessed. The impact of RvE1 on inflamed hDPSCs proliferation, proinflammatory gene expression (tumor necrosis factor alpha [TNF-α]), alkaline phosphatase activity, and alizarin red S staining was evaluated. Results: Scanning electron microscopy analysis demonstrated a highly porous interconnected microstructure. Release kinetics showed gradual RvE1 release peaking at day 14. Cumulative degradation of the CMC scaffold at 28 days was 57.35%. Inflamed hDPSCs exposed to 200 nM RvE1-CMC scaffold exhibited significantly improved viability compared to 100 nM. Both RvE1-CMC scaffolds significantly suppressed the expression of TNF-α at 7 days. Alkaline phosphatase activity was enhanced by both RvE1 concentrations on days 7 and 14. Alizarin red staining revealed superior mineralization potential of 200 nM RvE1 on days 14 and 21. Conclusions: This study concludes 200 nM RvE1-CMC scaffold is a promising therapy for inflamed pulp conditions, enhancing cell proliferation and biomineralization potential in inflamed hDPSCs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.